Arryx Announces Completion of Acquisition by Haemonetics
BRAINTREE, MA AND CHICAGO, IL, – Arryx Inc. reports the completion of its previously announced acquisition by Haemonetics Corporation (NYSE:HAE) effective July 18th, 2006. Arryx and Haemonetics have been collaborating since October 2004 in developing blood separation and processing technologies, and Haemonetics previously owned a 19% minority stake in Arryx. Arryx’s technology is expected to strengthen and diversify Haemonetics’ research capabilities.
Arryx’s research facilities, personnel, and operations will remain in Chicago. Arryx, Inc is now a wholly-owned subsidiary of Haemonetics.
Arryx’s proprietary technology uses light to form optical traps to move and manipulate small objects. Using laser beams and holograms, the systems can independently and in parallel hold, move, separate, and otherwise manipulate hundreds of microscopic and nanoscopic objects. Arryx’s first product, the BioRyx® 200 system, is used to handle cells and other objects in a laboratory environment.
Haemonetics (NYSE: HAE) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety. To learn more about Haemonetics’ products and markets, visit its web site at www.haemonetics.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The foregoing list should not be construed as exhaustive. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
